Exciting Presentation at Major Investment Conference
AUSTIN, Texas — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a leader in women's health diagnostics, is thrilled to announce that its CEO, Nicole Sandford, will speak at the H.C. Wainwright 26th Annual Global Investment Conference. This important event will take place from September 9-11, 2024, at a distinguished location in New York.
Announcement Details
The presentation by Aspira will be available on demand starting September 9 at 7:00 am ET for all registered attendees. Additionally, company executives will conduct one-on-one meetings on September 10 and 11, offering investors a unique chance to engage directly with the leadership team. Interested individuals are encouraged to reach out to their representatives at H.C. Wainwright for more information.
Accessing the Presentation and Future Updates
After the live presentation, a replay will be accessible on Aspira's website in the Investors section, ensuring that those who cannot attend live can still catch up on the essential insights shared during the conference.
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is dedicated to transforming women's health through cutting-edge, non-invasive diagnostic tools that utilize artificial intelligence. The company is focused on creating tests that aid healthcare professionals in the effective and accurate diagnosis of gynecologic diseases.
Innovative Testing Solutions
The comprehensive OvaSuite, which includes OvaWatch and Ova1Plus, features a range of blood tests designed for the detection of ovarian cancer. With over 1.2 million women diagnosed with adnexal masses each year in the U.S., these tests are crucial. OvaWatch has an impressive negative predictive value of 99%, making it an essential assessment tool for women at risk of ovarian cancer.
Future Directions in Diagnostics
Looking forward, Aspira is broadening its test pipeline with the ambitious aim of meeting non-invasive diagnostic needs for conditions such as endometriosis, which affects millions globally. The OvaMDx risk assessment is intended to improve the sensitivity and accuracy of current tests by integrating a combination of microRNA and protein biomarkers along with patient information. Furthermore, the EndoCheck test seeks to transform endometriosis diagnosis through non-invasive techniques.
Investor Relations Contact Information
Contact:
Nicole Sandford
Chief Executive Officer
Investors@aspirawh.com
Frequently Asked Questions
What is the H.C. Wainwright Conference?
This conference serves as a key platform for companies to share their financial and operational insights with potential investors and industry professionals.
Who is representing Aspira Women’s Health at the conference?
The CEO, Nicole Sandford, will be presenting for Aspira, discussing the company’s innovative diagnostic solutions.
When will attendees be able to access the presentation?
The on-demand presentation will be available starting September 9 at 7:00 am ET for those who are registered.
What types of products does Aspira provide?
Aspira offers AI-driven tests such as OvaWatch and Ova1Plus, which are designed for the diagnosis of ovarian cancer, as part of their innovative OvaSuite.
How does Aspira contribute to women's health?
Aspira is committed to developing non-invasive diagnostic solutions that enhance the diagnosis and treatment of gynecologic diseases, ultimately improving health outcomes for women.
